A recent study reveals alarming insights regarding the use of beta-blockers, a class of drugs typically prescribed after heart attacks. Historically deemed beneficial in mitigating risks of subsequent cardiac events, the research indicates that these medications may not only be ineffective for many patients but could also heighten the risk of hospitalization and mortality in certain women.
Dr. Valentin Fuster, senior author of the study and president of Mount Sinai Fuster Heart Hospital, remarked, “These findings will reshape all international clinical guidelines on the use of beta-blockers in men and women and should spark a long-needed, sex-specific approach to treatment for cardiovascular disease.”
Conducted as part of a comprehensive clinical trial, the findings highlight that women exhibiting minimal heart damage following a heart attack found no advantage in taking beta-blockers. In fact, those who did were at greater risk for subsequent heart attacks and nearly three times more likely to die than their counterparts not receiving the drug, as reported in the European Heart Journal. The study findings will also be presented at the European Society of Cardiology Congress in Madrid.
Dr. Borja Ibáñez, lead author and scientific director of Madrid’s National Center for Cardiovascular Investigation, noted, “This was especially true for women receiving high doses of beta-blockers.” The study’s participants represented the largest group of women ever included in research specifically analyzing the effects of beta-blockers post-myocardial infarction.
It is essential to point out that these findings apply specifically to women with a left ventricular ejection fraction (LVEF) above 50%. LVEF measures how well the heart pumps oxygenated blood and is critical for assessing heart health. While beta-blockers remain the standard treatment for patients with an LVEF below 40%, women with normal function may not require the same intervention.
Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver, cautioned about the potential side effects of beta-blockers, which can include low blood pressure, fatigue, erectile dysfunction, and mood swings. He emphasized the importance of weighing these risks against the potential benefits of the medication.
One question arising from the study is why beta-blockers may harm women more than men. Dr. Freeman explained that women often have smaller hearts and might be more sensitive to medications. “Some of that may have to do with size, and some may involve factors we have yet to fully understand,” he said.
Historically, research focused predominantly on male cardiovascular health, leading to gaps in understanding how heart disease manifests in women. While men often exhibit traditional symptoms like chest pain due to predominant plaque buildup in major arteries, women might experience more atypical presentations, including back pain and shortness of breath.
The analysis of the impact of beta-blockers on women is part of a larger clinical trial named REBOOT. This trial followed 8,505 patients treated for heart attacks across 109 hospitals in Spain and Italy over a span of nearly four years. Results were published in The New England Journal of Medicine.
Dr. Fuster stated, “We found no benefit in using beta-blockers for men or women with preserved heart function after heart attack despite this being the standard of care for some 40 years.” This revelation likely reflects advancements in other treatments, such as early intervention with stents and blood thinners after a heart attack.
Despite recent findings, about 80% of patients globally are still prescribed beta-blockers following heart attacks, largely due to existing medical guidelines that have not yet integrated these new insights. “While we often test new drugs, it’s much less common to rigorously question the continued need for older treatments,” Ibáñez added.
Interestingly, a separate meta-analysis of patients with LVEF levels between 40% and 50% found that these individuals may still benefit from beta-blockers. This subgroup exhibited a 25% reduction in composite outcomes, which included new heart attacks and heart failure.
As the medical community grapples with these significant findings, the emphasis on personalized treatment approaches tailored by gender is more critical than ever for improving cardiovascular care.
